Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC


Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the exploration of cabozantinib (Cabometyx) in the neoadjuvant setting in renal cell carcinoma (RCC).

Agents such as cabozantinib could have a potential role in the neoadjuvant or adjuvant setting in patients with nonmetastatic RCC, although investigators are still studying whether these agents are viable in these spaces, Jonasch says. More clinical trials are needed in the neoadjuvant and adjuvant settings to better determine the best treatment strategies for patients with nonmetastatic RCC, Jonasch adds.

Although neoadjuvant strategies have been effective in other disease types, no studies thus far have demonstrated the effectiveness of neoadjuvant therapy in RCC, Jonasch continues. It is unknown if cabozantinib could have a role in the neoadjuvant setting; however, that question needs to be answered in clinical trials, Jonasch concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD